2007 Diabetes Patients Provider 
The Health Policy Exchange
MAY 20, 2013
Unfortunately, recent case studies have illustrated that FDA approval does not necessarily provide assurances of effectiveness and safety. Very quickly, the market included nearly all dialysis patients, not just the roughly 16 percent who required blood transfusions. The size of average doses would more than triple.
GeriPal
FEBRUARY 17, 2022
I tell this story because these issues don’t typically register as more than a nuisance for clinicians, who frequently don’t understand why their older patient with osteoporosis is not taking a bisphosphonate. But our patients are walking with their feet, and adherence to bisphosphonates for osteoporosis is poor and decreases with time.
Expert insights. Personalized for you.
130 
Let's personalize your content